Excessive daytime sleepiness (EDS) is an underdiagnosed and undertreated condition that negatively impacts health and quality of life in people with obstructive sleep apnea (OSA). Residual EDS can continue to affect patients after sleep apnea therapy is optimized. In this program, expert faculty discuss guideline-supported recommendations for diagnosis and assessment of EDS in OSA and appropriate uses of novel and emerging agents for pharmacologic treatment. An interwoven case illustrates patient-centered strategies for management of EDS in the setting of OSA.
In Collaboration With the Association of Pulmonary Advanced Practice Providers
Interactive video lecture
After completing this activity, participants should be better able to:
- Apply guideline-supported recommendations for diagnosis and assessment of EDS in OSA
- Develop personalized management strategies for EDS in OSA
- Determine appropriate uses of novel and emerging agents for the pharmacologic treatment of EDS in OSA
NPs and PAs in pulmonary medicine
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Corinne R. Young, MSN, FNP-C, FCCP, Association of Pulmonary Advanced Practice Providers, Colorado Springs, Colorado
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 27, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: John Hardisty, MS, MSPAS, PA-C, Colorado Springs Pulmonary Consultants, Colorado Springs, Colorado
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program is cosupported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; Genentech, a member of the Roche Group; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; and Mylan Specialty L.P.
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Ms Cartwright has no relevant financial relationships to disclose.
Dr Doghramji: consulting fees: Eisai, Idorsia, Imbrium, Pfizer; contracted research/consulting fees: Harmony, Inspire, Jazz; ownership interest: Merck.
Ms Young has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the evaluation form
The estimated time to complete this activity is 1.00 hour.
Release date: January 28, 2022
Expiration date: January 27, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103121PBC-7C